Avelas Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Avelas Biosciences's estimated annual revenue is currently $1.1M per year.
- Avelas Biosciences's estimated revenue per employee is $217,000
Employee Data
- Avelas Biosciences has 5 Employees.
- Avelas Biosciences grew their employee count by -17% last year.
Avelas Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Senior Biomedical Engineer III | Reveal Email/Phone |
4 | President and CEO | Reveal Email/Phone |
Avelas Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Avelas Biosciences?
Avelas Biosciences is a clinical-stage biotechnology company and a pioneer in the field of intraoperative fluorescent cancer imaging. The company is focused on developing pegloprastide (also known as AVB-620), a novel drug-device combination product for use during cancer surgery. Pegloprastide is designed to improve surgery by detecting cancer in real time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries.
keywords:N/AN/A
Total Funding
5
Number of Employees
$1.1M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 5 | 0% | N/A |
#2 | $0.8M | 5 | 0% | N/A |
#3 | $0.4M | 5 | 0% | N/A |
#4 | $0.4M | 6 | 0% | N/A |
#5 | $0.9M | 6 | 0% | N/A |